RAGE Biotech Pty Ltd is a pharmaceutical start-up company developing novel therapeutics for patients with difficult-to-treat inflammatory disease. With our proprietary RNA therapeutics and peptide technologies, we are developing drugs targeting the Receptor for Advanced Glycation End-products (RAGE), a clinically important, pro-inflammatory ‘sensing’ receptor. Our most advanced programme is an inhaled drug for lung diseases where inflammation is a problem. RAGE Biotech was formed in 2020 with investments from IP Group, Monash Investment Holdings, the University of Western Australia and the Perron Instute.
Company Details
- Employees
- 8
- Founded
- -
- Address
- Melbourne, Au
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- ragebiotech.com
- Keywords
- in inhaled biologics.
- HQ
- Melbourne
Rage Biotech Questions
Rage Biotech's website is ragebiotech.com
Rage Biotech's LinkedIn profile is https://au.linkedin.com/company/rage-biotech
Rage Biotech has
8 employees.
View email and phone details for 8
employees at Rage Biotech.
Rage Biotech's industry is
Biotechnology Research
Rage Biotech's top competitors are
Metabix Biotech,
Pharmala Biotech Inc. (Mdma.cse),
Optieum Biotechnologies Inc.,
Hydregen,
Andson Biotech,
Hhv Biotech,
Lumatix Biotech,
Mxt Biotech,
Atanis Biotech Ag,
Hera Biotech.
Rage Biotech's categories are Biotechnology Research
Rage Biotech's founding year is 2020
